Incannex Healthcare Limited

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

First patient dosing has commenced in DReAMzz, a Phase 2 crossover dose-optimization study of Incannex's lead asset IHL-42X in obstructive sleep apnea, run across 13 U.S. sites with FDA feedback incorporated into the protocol. The USPTO granted a U.S. composition and methods-of-treatment patent covering IHL-42X with a baseline expiry of July 9, 2040; the program holds FDA Fast Track designation and follows positive RePOSA Phase 2 results with statistically significant apnea-hypopnea index reductions of up to 83 percent. As of August 31, 2026, Incannex held approximately $70 million in cash with no debt, supported by more than A$11.2 million in non-dilutive Australian R&D tax incentive capital received during 2026. The update recaps milestones rather than presenting new data; the next catalyst is DReAMzz dose-selection output, which management says is designed to support entry into a Phase 3 registration program for IHL-42X.

•2mo ago

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Incannex Healthcare announced the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, an oral treatment for obstructive sleep apnea. The study builds on prior Phase 2 RePOSA results where IHL-42X showed statistically significant reductions in apnea-hypopnea index, with individual reductions of up to 83%, and leverages the program's FDA Fast Track designation. All 14 clinical trial sites have Institutional Review Board approval, and the study aims to optimize dose selection to support the planned Phase 3 development program.

•2mo ago

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

Incannex received a final R&D Tax Incentive refund of A$5.1 million from the Australian Government, bringing total non-dilutive capital received in 2026 to over A$11.2 million. The funds result from the amendment of the FY25 income tax return following approval of overseas findings, bolstering the company's debt-free balance sheet. Management plans to deploy the capital to advance its clinical pipeline, including assets IHL-42X and PSX-001, while pursuing shareholder-focused initiatives.

•2mo ago

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Incannex Healthcare has commenced participant screening in its DReAMzz Phase 2 dose-confirmation study for IHL-42X, a treatment for obstructive sleep apnea. The study aims to optimize dosing for Phase III development, supported by prior data showing up to an 83% reduction in Apnea-Hypopnea Index and a prior FDA Fast Track designation. The company targets a global market of an estimated one billion people with OSA, for which there are currently no FDA-approved oral pharmaceutical therapies.

•3mo ago

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

Incannex secured a U.S. patent for IHL-42X covering compositions and methods for treating obstructive sleep apnea, with protection extending to at least July 2040. The company is advancing IHL-42X through the DReAMzz Phase 2 dose optimization study, having already received FDA Fast Track designation and central IRB approval. Management emphasized the strengthened commercial moat and the significant market opportunity for an oral therapy in the underserved OSA market.

•4mo ago

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

Incannex Healthcare received A$6.04 million from the Australian Government’s R&D Tax Incentive Program, adding non-dilutive capital to its balance sheet. The company expects an additional A$5.1 million in similar refunds later in 2026, bringing total expected non-dilutive proceeds to over A$11.1 million. CEO Joel Latham highlighted that these funds support clinical programs like IHL-42X and PSX-001, as well as the company’s active share repurchase program, without issuing new shares.

•4mo ago

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Healthcare supports the new White House Executive Order aimed at accelerating access to psychedelic treatments for serious mental illness, stating that its PSX-001 program aligns with these federal goals. The company highlighted Phase 2 data for PSX-001, which demonstrated a statistically significant 12.8-point reduction in HAM-A anxiety scores versus placebo and a 44% clinical response rate. Management noted that with over $70 million in cash, no debt, and an active U.S. IND, the company is well-positioned to advance its pipeline in this more favorable regulatory environment.

•6mo ago